Clinical Trials
17 trialsNCT00427856 2016-07-22
Safety and Efficacy of Single Agent Obatoclax Mesylate (GX15-070MS) Followed by a Combination With Rituximab for Previously-untreated Follicular Lymphoma (FL)
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2 Completed
NCT00724841 2016-07-22
A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic Melanoma
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1/2 Terminated
NCT00405951 2016-07-21
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)in Combination With Docetaxel for the Treatment of Non-Small Cell Lung Cancer
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1/2 Completed
NCT00407303 2016-07-21
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1/2 Completed
NCT00682981 2016-07-21
A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1/2 Completed
NCT00538187 2015-12-04
Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00521144 2015-05-05
Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00719901 2015-01-12
Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT00438178 2014-05-12
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) for the Treatment of Hematological Malignancies
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1 Completed
NCT00600964 2014-05-12
A Phase I/II Study of GX15-070MS in Untreated CLL
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1 Completed
NCT00933985 2014-05-01
Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00612612 2013-09-30
Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00684918 2013-08-26
Study of Obatoclax in Previously Untreated Acute Myeloid Leukemia (AML)
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2 Completed
NCT01238146 2013-06-06
Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 1/2 Withdrawn
NCT01563601 2012-08-15
Efficacy and Safety of Obatoclax Mesylate in Combination With Carboplatin and Etoposide Compared With Carboplatin and Etoposide Alone in Chemotherapy-Naive Patients With Extensive-Stage Small Cell Lung Cancer
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 3 Withdrawn
NCT00359892 2012-08-06
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Hodgkin's Lymphoma
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2 Completed
NCT00918931 2011-11-04
Obatoclax for Systemic Mastocytosis
M.D. Anderson Cancer Center
Phase 2 Terminated